Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of Orelabrutinib combined with Obinutuzumab for previously untreated MZL.

Trial Details

NCT ID
NCT06566807
Phase
PHASE2
Sponsor
Huai'an First People's Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Orelabrutinib, obinutuzumab
Locations (sample)
  • Huai'an, Jiangsu, China|33.58861,119.01917

Key Eligibility Criteria

  • Aged ≥18 years, gender not limited;
  • Histopathologically confirmed CD20-positive marginal zone lymphoma including MALT, SMZL, NMZL;
  • MZL that has progressed, recurred, or is not suitable for local treatment after previous local treatment (local treatments include surgery, radioth…
  • Indication for treatment as judged by the investigator (symptomatic, with cytopenia, at risk of end-organ damage, bulky disease, persistent progres…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →